The latest price target for Adicet Bio (NASDAQ:ACET) was reported by Guggenheim on March 21, 2025. The analyst firm set a price target for $7.00 expecting ACET to rise to within 12 months (a possible 695.45% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Adicet Bio (NASDAQ:ACET) was provided by Guggenheim, and Adicet Bio reiterated their buy rating.

There is no last upgrade for Adicet Bio

The last downgrade for Adicet Bio Inc happened on September 11, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Adicet Bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adicet Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adicet Bio was filed on March 21, 2025 so you should expect the next rating to be made available sometime around March 21, 2026.

While ratings are subjective and will change, the latest Adicet Bio (ACET) rating was a reiterated with a price target of $7.00 to $7.00. The current price Adicet Bio (ACET) is trading at is $0.88, which is out of the analyst’s predicted range.